Article Text

See original article:

Download PDFPDF
Treatment of stable angina
  1. Itsik Ben-Dor,
  2. Alexander Battler
  1. Department of Cardiology, Rabin Medical Center, Beilinson Campus, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  1. Correspondence to:
    Professor Alexander Battler
    Department of Cardiology, Rabin Medical Center, 39 Jabotinsky Street, Petach Tikva, Israel 49100; abattler{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Coronary artery disease is still highly prevalent worldwide, and stable angina pectoris is one of its more common presentations. Stable angina is a clinical expression of myocardial ischaemia associated with fixed atherosclerotic coronary stenosis, which prevents the adaptation of coronary perfusion to an increased oxygen requirement. The goals of treatment include relief of symptoms, inhibition or slowing of disease progression, prevention of future cardiac events such as myocardial infarction (MI), and improved survival. This article reviews the treatment modalities currently available to alleviate the symptoms of chronic angina and to reduce the risk of future MI and cardiac death, including several novel pharmacological treatments, coronary revascularisation, as well as novel technologies that may benefit selected groups of patients who are refractory to both drugs and revascularisation (fig 1).

Figure 1

 Different modalities of treatment of stable angina. ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; EECP, enhanced external counter pulsation; PCAB, percutaneous in situ coronary artery bypass; PCVA, percutaneous in situ coronary venous arterialisation; PCI, percutaneous coronary intervention; TMR, transmyocardial laser revascularisation.


Three major classes of anti-ischaemia drugs are currently used in the medical management of angina pectoris: β-blockers, nitrates (short- and long-acting), and calcium channel antagonists (table 1). All three have been shown to prolong the duration of exercise before the onset of angina and ST segment depression as well as to decrease the frequency of angina. However, none prevents MI or death caused by coronary disease in patients being treated specifically for chronic stable angina.

View this table:
Table 1

 Treatments for stable angina

Although the clinical guidelines of the American College of Cardiology/American Heart Association (2002) and the European Society of Cardiology (2006) suggest that β-blockers be used as the first-line agents in patients with stable angina,1–,3 head-to-head comparative trials failed to demonstrate a greater antianginal efficacy for …

View Full Text


  • In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society